AstraZeneca

AZN – AstraZeneca plc Information and Vote Guidance 2024

AGM: 11th April 2024 Proxy deadline: 9th April 2024 ShareSoc provide this added value voting information service for Full Members only, providing background information on leading companies and AGM vote guidance. Below are links to the: 1. Stockopedia summary report. 2. Minerva Vote recommendations for the 11th April 2024 AGM based on their standard template. 3. Minerva detailed research report for the AGM. Summary of voting issues at this year’s AGM  The Minerva report highlights various issues and recommends voting against three of the resolutions. Readers should make their own ...

AZN – AstraZeneca plc Information and Vote Guidance 2023

ShareSoc introduced this new added value voting information service for Full Members only in 2021, providing background information on leading companies and AGM vote guidance. Initially, we are piloting this for FTSE30 companies, plus a few others in the FTSE100. We have decided to continue the pilot in 2023 and are looking at ways to improve our services to members. Below are links to the: 1. Stockopedia summary report. 2. Minerva Vote recommendations for the 27 April 2023 AGM based on their standard template.  3. ...

Kentz, Victoria, AstraZeneca, and SSE

A number of companies on which ShareSoc has commented recently were in the news today (23/6/2014) or over the preceding weekend. Let's cover each in turn: Kentz Kentz received a cash offer for the company of 935p from SNC-Lavalin this morning. That's a premium of 33% to the recent share price. With such a premium and the stated support for the offer from the directors, it looks likely to succeed.  This will avoid the directors of Kentz having to deal with the ...

AstraZeneca and Pfizer merger definitely off

Pfizer have conceded defeat in their proposed offer for AstraZeneca (AZN). Ian Read, the Chief Executive of Pfizer, said it was a "missed opportunity" for both the UK and for AZN shareholders. He also said we could have had the worlds largest pharmaceutical company domiciled in the UK which would have been good for science and manufacturing in this country. He surely has a point there. In addition he complained about the Takeover Panel rules as contributing to thwarting the deal, but ...

Thoughts on AstraZeneca

Shareholders in AstraZeneca are no doubt pleasantly surprised by the uplift in the share price following the offers from Pfizer. The share price has doubled in the last year on improving prospects with an even sharper increase in the last few weeks as soon as a bid was rumoured. That puts the company on a historic p/e of about 20 at the time of writing. AstraZeneca has of course been a dog for some years with falling revenue and earnings, a poor ...